Theravance Biopharma, Inc. (NASDAQ: TBPH), a key player in the healthcare sector, is carving its niche within the biotechnology industry. With a market capitalization of $884.18 million, this biopharmaceutical company focuses on developing and commercializing innovative medicines in the United States. As investors seek opportunities in a volatile market, Theravance’s unique position and strategic collaborations offer potential for growth.
At a current price of $17.03, Theravance’s stock has remained steady, showing no price change recently. The 52-week range mirrors the current price, indicating a period of stability. This stability is further supported by the technical indicators, with both the 50-day and 200-day moving averages aligning at $17.03. The Relative Strength Index (RSI) is currently at 0.00, suggesting the stock is neither overbought nor oversold.
Theravance’s valuation metrics reveal interesting insights. The Forward P/E ratio stands at 13.36, hinting at investor expectations for future earnings. However, other traditional valuation metrics such as the P/E ratio (Trailing), PEG ratio, Price/Book, and Price/Sales are not available, making it challenging to compare Theravance directly against its peers using these metrics.
The company’s performance metrics present a mixed picture. Despite a concerning revenue growth decline of 20.90%, the company boasts a strong Return on Equity (ROE) of 20.91%, which is a positive indicator of profitability relative to shareholder equity. The free cash flow of $5.3 million suggests that Theravance maintains some financial flexibility, potentially allowing for strategic investments or addressing operational needs without immediate need for external financing.
Analyst ratings for Theravance Biopharma are cautious, with three hold ratings and no buy or sell recommendations. The target price range is set between $17.00 and $19.00, with an average target of $17.67, offering a modest potential upside of 3.74%. This cautious optimism reflects the market’s current sentiment, focusing on the strategic developments and potential breakthroughs in Theravance’s pipeline.
Theravance’s product portfolio includes YUPELRI, a treatment for chronic obstructive pulmonary disease (COPD), and Ampreloxetine, which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). The strategic collaboration with Viatris Inc. for the commercialization of revefenacin, including YUPELRI, positions Theravance for potential future growth contingent on successful clinical outcomes and market acceptance.
Without a dividend yield and a payout ratio of 0.00%, Theravance Biopharma is not currently offering income returns to investors, which aligns with its growth-focused strategy typical of biopharmaceutical companies concentrating on reinvesting earnings into research and development.
Theravance Biopharma’s headquarters in South San Francisco, California, acts as a hub for its innovative research efforts. The company, now a subsidiary of Zymeworks Inc. as of September 2026, continues to expand its horizons in the biopharmaceutical landscape, taking bold strides in drug development and commercialization.
Investors considering Theravance Biopharma should weigh the company’s robust development pipeline and strategic alliances against the backdrop of its financial metrics and market stability. As the company advances its clinical trials and strategic partnerships, the potential for future growth and returns remains an intriguing prospect for those willing to navigate the inherent risks of biotechnology investments.
